ADVANCED PERFORMANCE.
EARLY RESORPTION. LONG-TERM DESOLVE SAFETY*.

*Leverages DESolve NX 4Y safety data, A. Abizaid, TCT 2016.
A NEW PERFORMANCE STANDARD FOR BRS

1. Reduced 120 µm strut thickness
2. Improved deliverability¹
3. Leverages DESolve platform

INTRODUCING TRANSFORM™ BALLOON TECHNOLOGY

Designed to:
- Enhance scaffold expansion in the most resistant segment of the lesion
- Minimize edge dissection during deployment
- Optimize concentric expansion

IMPROVED DELIVERABILITY¹

While maintaining the DESolve’s unique polymer characteristics, DESolve Cx PLUS advances acute performance of bioresorbable scaffolds.

¹ Data on file at Elixir Medical
**LEVERAGES THE DESOLVE PLATFORM**

The DESolve polymer is uniquely engineered to degrade in 6 months with near complete resorption at 1 year\(^1\)

This timely combination of degradation and resorption allows for early lumen and scaffold growth at 6 months.\(^2\)

Furthermore, DESolve unique degradation and resorption profile potentially addresses late and very late scaffold events that may relate to the persistent presence of the scaffold/polymer\(^3\) in other polymeric scaffolds which take 3-5 years to resorb.\(^4,5\)

At 4 years, the DESolve Nx study shows excellent safety with no late or very late definite scaffold thrombosis.\(^6\)

---

**SUSTAINED SAFETY THROUGH 4 YEARS**

<table>
<thead>
<tr>
<th>Definite Scaffold Thrombosis</th>
<th>DESolve Nx (n=125)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3 Years</td>
</tr>
<tr>
<td>Acute (0-1 day)</td>
<td>0</td>
</tr>
<tr>
<td>Sub Acute (2-30 days)</td>
<td>0</td>
</tr>
<tr>
<td>Late (31-365 days)</td>
<td>0</td>
</tr>
<tr>
<td>Very Late (&gt;365 days)</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

---

**UNIQUE SELF-CORRECTION DESIGNED TO REDUCE MALAPPOSITION & PREVENT CHRONIC RECOIL\(^7\)**

\(7\) Does not correct for under-deployment.

---

1. ~70% resorption in developmental preclinical data
3. Yamaji, K, Raeber L, Windecker S. What Determines long-term outcomes using fully bioresorbable scaffolds – the device, the operator or the lesion. Eurointervention 20 Feb 2017, vol 12:14
4. Rippy M., Vascular safety of Bioresorbable scaffolds made from biomaterials designed for use in interventional cardiology, EuroPCR 2014
**TRANSFORM™ BALLOON TECHNOLOGY**

- Balloon central segment expands to 0.25mm larger than the end segments at nominal pressure.
- 3mm length segments on proximal and distal ends expand to nominal diameter.
- Smooth dome-shaped transition.
- Single balloon material.

---

**DESOLVE CX PLUS ORDERING INFORMATION**

<table>
<thead>
<tr>
<th>Scaffold Diameter (mm)</th>
<th>Scaffold Length (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>BFR2514</td>
</tr>
<tr>
<td>3.0</td>
<td>BFR3014</td>
</tr>
<tr>
<td>3.5</td>
<td>BFR3514</td>
</tr>
</tbody>
</table>

Porcine Study 2030-029N – D90-10 – RCA Mid

---

Elixir Medical Corporate Headquarters
920 N McCarthy Blvd, Milpitas, CA 95035 USA
408.636.2000 | info@elixirmedical.com
www.ELIXIRMEDICAL.com

Elixir Medical Corporation specializes in developing products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide.

---

**INTERNATIONAL (OUS) USE ONLY**

Caution: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

Elixir, Innovation for Life, and DESolve are US and internationally registered trademarks of Elixir. ©2017 Elixir 04/30

DESolve CX PLUS is CE Mark approved; All sizes may not be available in all geographies.